UnitedHealthcare Community Plan

Praluent
Prior Authorization Request Form

Please complete this **entire** form and fax it to: **866-940-7328**. If you have questions, please call **800-310-6826.**
This form may contain multiple pages. Please complete all pages to avoid a delay in our decision.
Allow at least 24 hours for review.

Section A – Member Information

First Name:	Last Name:	Member ID:
Address:		
City:	State:	ZIP Code:
Phone:	DOB:	Allergies:
Primary Insurance Information (if any):		

Is the requested medication: □ New or □ Continuation of Therapy? If continuation, list start date: _____

Is this patient currently hospitalized? □ Yes □ No If recently discharged, list discharge date: _____

Section B - Provider Information

First Name:		Last Name:		M.D./D.O.
Address:		City:	State:	ZIP code:
Phone:	Fax:	NPI #:	Specialty:	
Office Contact Name / Fax attention to:				

Section C - Medical Information

Medication:	**Strength:**
Directions for use:	**Quantity:**
Diagnosis (Please be specific & provide as much information as possible)**:**	**ICD-10 CODE:**

Is this member pregnant? □ Yes □ No If yes, what is this member's due date? _____

Section D – Previous Medication Trials

Medication Name	Strength	Directions	Dates of Therapy	Reason for failure / discontinuation

Section E – Additional information and Explanation of why preferred medications would not meet the patient's needs: Please refer to the patient's PDL at www.uhcprovider.com for a list of preferred alternatives

UnitedHealthcare Community Plan

Praluent
Prior Authorization Request Form

Member First name:	Member Last name:	Member DOB:

Clinical and Drug Specific Information

ALL REQUESTS

□ Yes □ No	**Does the prescriber attest that the information provided below is true and accurate to the best of their knowledge and they understand that UnitedHealthcare may perform a routine audit and request the medical information necessary to verify the accuracy of the information provided?**
□ Yes □ No	**Does the patient have any of the following diagnoses?** *(If yes, check which applies)* □ Atherosclerotic cardiovascular disease (ASCVD) □ Heterozygous familial hypercholesterolemia (HeFH)
□ Yes □ No	**Will medical records (e.g., chart notes, laboratory values) documenting the patient has been receiving at least 12 consecutive weeks of high-intensity statin therapy [i.e. atorvastatin 40-80 mg, rosuvastatin 20-40 mg] and will continue to receive high intensity statin at maximally tolerated dose be submitted?** *DOCUMENTATION REQUIRED*
□ Yes □ No	**Is the patient is unable to tolerate high-intensity statin as evidenced by any of the following intolerable and persistent (i.e. more than 2 weeks) symptoms?** *(If yes, check which applies)* □ Myalgia (muscle symptoms without creatine kinase [CK] elevations) □ Myositis (muscle symptoms with CK elevations < 10 times upper limit of normal [ULN])
□ Yes □ No	**Will medical records (e.g., chart notes, laboratory values) documenting the patient has been receiving at least 12 consecutive weeks of moderate-intensity statin therapy [i.e. atorvastatin 10-20 mg, rosuvastatin 5- 10 mg, simvastatin ≥ 20 mg, pravastatin ≥ 40 mg, lovastatin 40 mg, Lescol XL (fluvastatin XL) 80 mg, fluvastatin 40 mg twice daily or Livalo (pitavastatin) ≥ 2 mg] and will continue to receive a moderate-intensity statin at maximally tolerated dose be submitted?** *DOCUMENTATION REQUIRED*
□ Yes □ No	**Will medical records (e.g., chart notes, laboratory values) documenting the patient has been receiving at least 12 consecutive weeks of low-intensity statin therapy [i.e. simvastatin 10 mg, pravastatin 10-20 mg, lovastatin 20 mg, fluvastatin 20-40 mg, or Livalo (pitavastatin) 1 mg] and will continue to receive a low-intensity statin at maximally tolerated dose be submitted?** *DOCUMENTATION REQUIRED*
□ Yes □ No	**Is the patient is unable to tolerate low- or moderate-, and high-intensity statins as evidenced by any of the following intolerable and persistent (i.e. more than 2 weeks) symptoms for low- or moderate-, and high-intensity statins?** *(If yes, check which applies)* □ Myalgia (muscle symptoms without CK elevations) □ Myositis (muscle symptoms with CK elevations < 10 times upper limit of normal [ULN])
□ Yes □ No	**Will medical records (e.g., chart notes, laboratory values) documenting the patient has a labeled contraindication to all statins be submitted?** *DOCUMENTATION REQUIRED*
□ Yes □ No	**Will medical records (e.g., chart notes, laboratory values) documenting the patient has experienced rhabdomyolysis or muscle symptoms with statin treatment with CK elevations > 10 times the upper limit of normal (ULN) be submitted?** *DOCUMENTATION REQUIRED*
□ Yes □ No	**Will medical record (e.g., laboratory values) documenting any of the following LDL-C values while on maximally tolerated lipid lowering therapy for a minimum of at least 12 weeks within the last 120 days be submitted?** *(If yes, check which applies)* □ LDL-C ≥ 100 mg/dL with ASCVD □ LDL-C between 70 mg/dL and 99 mg/dL with ASCVD □ LDL-C ≥ 130 mg/dL without ASCVD □ LDL-C between 100 mg/dL and 129 mg/dL without ASCVD
□ Yes □ No	**Will medical record (e.g., chart notes, laboratory values) documenting the patient has any of the following be submitted?** *(If yes, check which applies. DOCUMENTATION REQUIRED)* □ Patient has been receiving at least 12 consecutive weeks of ezetimibe (Zetia) therapy as adjunct to maximally tolerated statin therapy □ Patient has a history of contraindication or intolerance to ezetimibe
□ Yes □ No	**Will Praluent be used as an adjunct to a low-fat diet and exercise?**
□ Yes □ No	**Is Praluent prescribed by any of the following?** *(If yes, check which applies)* □ Cardiologist □ Endocrinologist □ Lipid specialist
□ Yes □ No	**Will Praluent be used in combination with another proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor [e.g., Repatha (evolocumab)]?**

UnitedHealthcare Community Plan

Praluent
Prior Authorization Request Form

Member First name:	Member Last name:	Member DOB:

ARTHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD)	
□ **Yes** □ **No**	**Does the patient have ASCVD as confirmed by any of the following?** *(If yes, check which applies)* □ Acute coronary syndromes □ Coronary or other arterial revascularization □ History of myocardial infarction □ Peripheral arterial disease presumed to be of atherosclerotic origin □ Stable or unstable angina □ Stroke □ Transient ischemic attack
HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HeFH)	
□ **Yes** □ **No**	**Was the patient's diagnosis of HeFH confirmed by a pre-treatment low-density lipoprotein cholesterol (LDL-C) of any of the following?** *(If yes, check which applies)* □ Greater than 190 mg/dL □ Greater than 155 mg/dL if less than 16 years of age
□ **Yes** □ **No**	**Does the patient have any of the following?** *(If yes, check which applies)* □ Family history of myocardial infarction in first-degree relative < 60 years of age □ Family history of myocardial infarction in second-degree relative < 50 years of age □ Family history of LDL-C greater than 190 mg/dL in first- or second-degree relative □ Family history of heterozygous or homozygous familial hypercholesterolemia in first- or second-degree relative □ Family history of tendinous xanthomata and/or arcus cornealis in first- or second degree relative
□ **Yes** □ **No**	**Will medical records (e.g., chart notes, laboratory values) documenting the patient has any of the following be submitted?** *(If yes, check which applies. DOCUMENTATION REQUIRED)* □ Arcus cornealis before age 45 □ Functional mutation in LDL (low density lipoprotein), apoB (apolipoprotein B), or PCSK9 (proprotein convertase subtilisin/kexin type 9) gene □ Tendinous xanthomata
CONTINUATION OF THERAPY	
□ **Yes** □ **No**	**Does the patient continue to receive a statin at a maximally tolerated dose (unless patient has documented inability to take statins)?**
□ **Yes** □ **No**	**Is the patient continuing a low-fat diet and exercise regimen?**
□ **Yes** □ **No**	**Is Praluent prescribed by any of the following?** *(If yes, check which applies)* □ Cardiologist □ Endocrinologist □ Lipid specialist
□ **Yes** □ **No**	**Will medical records (e.g. chart notes, laboratory values) documenting the patient has low density lipoprotein cholesterol (LDL-C) reduction while on Praluent therapy be submitted?** *DOCUMENTATION REQUIRED*
□ **Yes** □ **No**	**Will Praluent be used in combination with another proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor [e.g., Repatha (evolocumab)]?**

Provider Signature: _____ **Date:** _____

Confidentiality Notice: This transmission contains confidential information belonging to the sender and UnitedHealthcare. This information is intended only for the use of UnitedHealthcare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this telecopy in error, please notify the sender immediately.